Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,494 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,594 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02667743 | Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC | unknown | Phase 3 | 454 | Shanghai Yizhong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04803266 | Elective Internal Mammary Node Irradiation in Women With Node-positive Breast Cancer | unknown | Phase 3 | 747 | Yonsei UniversityOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT04799314 | PD-1 Inhibitor Tislelizumab Maintenance Therapy in R/R DLBCL Patients After ASCT | unknown | Phase 3 | 132 | Ruijin HospitalOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT02085655 | PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma | unknown | Phase 3 | 264 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT03668496 | A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC | unknown | Phase 3 | 390 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04797806 | Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC(SAINT) | unknown | Phase 3 | 206 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT04665609 | Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC | unknown | Phase 3 | 80 | Chinese PLA General HospitalOTHER | 1 | Mar 4, 2021 | clinicaltrials |
| NCT04780750 | Concurent Chemoradiotherapy in Head and Neck Cancers | unknown | Phase 3 | 60 | Assiut UniversityOTHER | 0 | Mar 3, 2021 | clinicaltrials |
| NCT03520478 | A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer | unknown | Phase 3 | 654 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 4 | Mar 2, 2021 | clinicaltrials |
| NCT04691063 | The Study is Being Conducted to Evaluate the Efficacy and Safety of SHR-1316 in Combination With Chemo-radiotherapy in Patients With LS-SCLC. | unknown | Phase 3 | 486 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 26, 2021 | clinicaltrials |
| NCT03417622 | Wide Margin vs. Narrow Margin in Postneoadjuvant Lumpectomy | unknown | Phase 3 | 370 | Mansoura UniversityOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT04766359 | Paclitaxel (Albumin-bound) Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma | unknown | Phase 3 | 364 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Feb 23, 2021 | clinicaltrials |
| NCT04761172 | NIR Fluorescence Imaging With ICG for the Intraoperative Identification of Gastrointestinal Stromal Cell Tumours | unknown | Phase 2 / Phase 3 | 10 | Leiden University Medical CenterOTHER | 1 | Feb 18, 2021 | clinicaltrials |
| NCT02526953 | Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients | unknown | Phase 3 | 314 | Blokhin's Russian Cancer Research CenterOTHER | 0 | Feb 9, 2021 | clinicaltrials |
| NCT04103697 | Neoadjuvant Chemotherapy in Patients With Intermediate Risk Upper and Mid Rectal Cancer(RuCorT-01) | unknown | Phase 3 | 560 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT04134897 | Neoadjuvant Chemotherapy in Patients With Moderate Risk Mid Rectal Cancer(RuCorT-02) | unknown | Phase 3 | 316 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT04135313 | Induction and Consolidation Chemotherapy in Patients With Locally Advanced CRM-positive Rectal Cancer(RuCorT-03) | unknown | Phase 3 | 540 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT04229355 | DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma | unknown | Phase 3 | 90 | Guangxi Medical UniversityOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT04342936 | Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma | unknown | Phase 3 | 56 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 8, 2021 | clinicaltrials |
| NCT04490421 | Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. | unknown | Phase 3 | 45 | Fuzhou General HospitalOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT04300829 | Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients(CICA-RT) | unknown | Phase 3 | 248 | Centre Leon BerardOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT00433433 | Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's Lymphoma(H10) | unknown | Phase 3 | 1,952 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04736186 | Prevention and Treatment of Pyrrolitinib-associated Diarrhea | unknown | Phase 2 / Phase 3 | 470 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT04500145 | Simultaneous Integrated Boost vs. Routine IMRT in Limited-stage Small-cell Lung Cancer | unknown | Phase 3 | 350 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT01817023 | The Role of Concurrent Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma(NPC) in the Era of IMRT | unknown | Phase 3 | 590 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT03908372 | Optimized Treatment Strategies for Early and Medium Stage Nasopharyngeal Carcinoma | unknown | Phase 2 / Phase 3 | 120 | Chinese Academy of Medical SciencesOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT04486651 | HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer | unknown | Phase 3 | 560 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Jan 28, 2021 | clinicaltrials |
| NCT00667888 | A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation | unknown | Phase 3 | 225 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT03794440 | A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. | unknown | Phase 2 / Phase 3 | 595 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 22, 2021 | clinicaltrials |
| NCT04712032 | Anastomotic Leakage and Value Of Indocyanine Green in Decreasing Leakage Rates(AVOID) | unknown | Phase 3 | 978 | Leiden University Medical CenterOTHER | 1 | Jan 15, 2021 | clinicaltrials |
| NCT04687163 | Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial | unknown | Phase 3 | 400 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT03716518 | Herbal Treatment to Improve Chemotherapy Delivery(HATCHED) | unknown | Phase 3 | 400 | Xiyuan Hospital of China Academy of Chinese Medical SciencesOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT04705909 | Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer | unknown | Phase 2 / Phase 3 | 60 | Mansoura UniversityOTHER | 1 | Jan 12, 2021 | clinicaltrials |
| NCT04690283 | Yiqi Wenjing Prescriptions Preventive Efficacy of Oxaliplatin-induced Peripheral Neuropathy Clinical Trial(YWPPEOPNCT) | unknown | Phase 3 | 360 | Nanjing NingQi Medicine Science and Technology Co., Ltd.INDUSTRY | 0 | Dec 30, 2020 | clinicaltrials |
| NCT03530085 | Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT | unknown | Phase 2 / Phase 3 | 60 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT04665986 | Neoadjuvant Study of Navelbine in Patients With HER2 Positive Breast Cancer | unknown | Phase 3 | 50 | Zhejiang Cancer HospitalOTHER | 0 | Dec 14, 2020 | clinicaltrials |
| NCT04667351 | HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial | unknown | Phase 3 | 400 | Sun Yat-sen UniversityOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT04648917 | GASC1 Inhibitor Caffeic Acid for Squamous Esophageal Cell Cancer (ESCC)(GiCAEC) | unknown | Phase 3 | 80 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT04646954 | DNA Methylation Testing for the Screening of Uterine Cervical Lesion | unknown | Phase 3 | 12,000 | Lei LiOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT00303784 | Prostate Adenocarcinoma TransCutaneous Hormones(PATCH) | unknown | Phase 3 | 2,200 | University College, LondonOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT03070262 | The Efficacy and Safety of Caffeic Acid for Esophageal Cancer(CAEC) | unknown | Phase 3 | 300 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 1 | Nov 27, 2020 | clinicaltrials |
| NCT03898921 | RFA vs. SBRT for Small HCC | unknown | Phase 3 | 270 | Sun Yat-sen UniversityOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT04642924 | SGM-101 in Locally Advanced and Recurrent Rectal Cancer(SGM-LARRC) | unknown | Phase 2 / Phase 3 | 203 | Leiden University Medical CenterOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT00410683 | Radiation Therapy in Treating Patients With Non Small Cell Lung Cancer That Has Been Completely Removed by Surgery(LUNG ART) | unknown | Phase 3 | 500 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04000698 | Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias | unknown | Phase 3 | 25 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT03909724 | Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC)(SUNRISE-CRC) | unknown | Phase 2 / Phase 3 | 60 | Amsterdam UMC, location VUmcOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT04183478 | The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer | unknown | Phase 2 / Phase 3 | 600 | RenJi HospitalOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT00736320 | HD16 for Early Stage Hodgkin Lymphoma(HD16) | unknown | Phase 3 | 1,150 | University of CologneOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT03402048 | The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial(EPIC) | unknown | Phase 3 | 567 | University of Turin, ItalyOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT03288870 | Efficacy, Safety and Pharmacokinetics of BCD-100 (Anti-PD-1) Monotherapy as Second Line Treatment in Patients With Non-Small Cell Lung Cancer (DOMINUS)(DOMINUS) | unknown | Phase 2 / Phase 3 | 218 | BiocadINDUSTRY | 2 | Oct 29, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Mar 17, 2021source: clinicaltrials